Literature DB >> 12970786

t(5;14)/HOX11L2-positive T-cell acute lymphoblastic leukemia. A collaborative study of the Groupe Français de Cytogénétique Hématologique (GFCH).

R Berger1, N Dastugue, M Busson, J Van Den Akker, C Pérot, P Ballerini, A Hagemeijer, L Michaux, C Charrin, M P Pages, F Mugneret, J Andrieux, P Talmant, C Hélias, L Mauvieux, M Lafage-Pochitaloff, M-J Mozziconacci, P Cornillet-Lefebvre, I Radford, V Asnafi, C Bilhou-Nabera, F Nguyen Khac, C Léonard, F Speleman, B Poppe, C Bastard, S Taviaux, B Quilichini, C Herens, M-J Grégoire, H Cavé, O A Bernard.   

Abstract

To accurately estimate the incidence of HOX11L2 expression, and determine the associated cytogenetic features, in T-cell acute lymphoblastic leukemia (T-ALL), the Groupe Français de Cytogénétique Hématologique (GFCH) carried out a retrospective study of both childhood and adult patients. In total, 364 patients were included (211 children </=15 years and 153 adults), and 67 (18.5%) [47 children (22.4%) and 20 adults (13.1%)] were shown to either harbor the t(5;14)q35;q32) translocation or express the HOX11L2 gene or both. Most of the common hematological parameters did not show significant differences within positive and negative populations, whereas the incidence of CD1a+/CD10+ and cytoplasmic CD3+ patients was significantly higher in positive than in negative children. Out of the 63 positive patients investigated by conventional cytogenetics, 32 exhibited normal karyotype, whereas the others 31 showed clonal chromosome abnormalities, which did not include classical T-ALL specific translocations. Involvement of the RANBP17/HOX11L2 locus was ascertained by fluorescence in situ hybridization in six variant or alternative (three-way translocation or cytogenetic partner other than 14q32) translocations out of the 223 patients. Our results also show that HOX11L2 expression essentially occurs as a result of a 5q35 rearrangement, but is not associated with another identified T-ALL specific recurrent genetic abnormality, such as SIL-TAL fusion or HOX11 expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970786     DOI: 10.1038/sj.leu.2403061

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  12 in total

1.  Identification of RANBP16 and RANBP17 as novel interaction partners for the bHLH transcription factor E12.

Authors:  Jun-Ho Lee; Shengli Zhou; Cynthia M Smas
Journal:  J Cell Biochem       Date:  2010-09-01       Impact factor: 4.429

Review 2.  Emerging technologies in paediatric leukaemia.

Authors:  Amanda Dixon-McIver
Journal:  Transl Pediatr       Date:  2015-04

3.  TLX1/HOX11-mediated disruption of primary thymocyte differentiation prior to the CD4+CD8+ double-positive stage.

Authors:  Bronwyn M Owens; Teresa S Hawley; Lisa M Spain; Kristi A Kerkel; Robert G Hawley
Journal:  Br J Haematol       Date:  2006-01       Impact factor: 6.998

Review 4.  The effect of TLX3 expression on the prognosis of pediatric T cell acute lymphocytic leukemia--a systematic review.

Authors:  Jiexian Ma; Jinsheng Hua; Yinghao Sha; Yanhui Xie
Journal:  Tumour Biol       Date:  2014-07-06

5.  Integrated genome-wide genotyping and gene expression profiling reveals BCL11B as a putative oncogene in acute myeloid leukemia with 14q32 aberrations.

Authors:  Saman Abbas; Mathijs A Sanders; Annelieke Zeilemaker; Wendy M C Geertsma-Kleinekoort; Jasper E Koenders; Francois G Kavelaars; Zabiollah G Abbas; Souad Mahamoud; Isabel W T Chu; Remco Hoogenboezem; Justine K Peeters; Ellen van Drunen; Janneke van Galen; H Berna Beverloo; Bob Löwenberg; Peter J M Valk
Journal:  Haematologica       Date:  2014-01-17       Impact factor: 9.941

6.  Homeobox protein TLX3 activates miR-125b expression to promote T-cell acute lymphoblastic leukemia.

Authors:  Laurent Renou; Pierre-Yves Boelle; Caroline Deswarte; Salvatore Spicuglia; Aissa Benyoucef; Julien Calvo; Benjamin Uzan; Mohamed Belhocine; Agata Cieslak; Judith Landman-Parker; Andre Baruchel; Vahid Asnafi; Françoise Pflumio; Paola Ballerini; Irina Naguibneva
Journal:  Blood Adv       Date:  2017-05-04

7.  Fusion of platelet-derived growth factor receptor β to CEV14 gene in chronic myelomonocytic leukemia: A case report and review of the literature.

Authors:  Sheng-Lan Gong; Meng-Qiao Guo; Gu-Sheng Tang; Chun-Ling Zhang; Hui-Ying Qiu; Xiao-Xia Hu; Jian-Min Yang
Journal:  Oncol Lett       Date:  2015-11-18       Impact factor: 2.967

8.  Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy.

Authors:  Cigall Kadoch; Diana C Hargreaves; Courtney Hodges; Laura Elias; Lena Ho; Jeff Ranish; Gerald R Crabtree
Journal:  Nat Genet       Date:  2013-05-05       Impact factor: 38.330

9.  The TLX1 oncogene drives aneuploidy in T cell transformation.

Authors:  Kim De Keersmaecker; Pedro J Real; Giusy Della Gatta; Teresa Palomero; Maria Luisa Sulis; Valeria Tosello; Pieter Van Vlierberghe; Kelly Barnes; Mireia Castillo; Xavier Sole; Michael Hadler; Jack Lenz; Peter D Aplan; Michelle Kelliher; Barbara L Kee; Pier Paolo Pandolfi; Dietmar Kappes; Fotini Gounari; Howard Petrie; Joni Van der Meulen; Frank Speleman; Elisabeth Paietta; Janis Racevskis; Peter H Wiernik; Jacob M Rowe; Jean Soulier; David Avran; Hélène Cavé; Nicole Dastugue; Susana Raimondi; Jules P P Meijerink; Carlos Cordon-Cardo; Andrea Califano; Adolfo A Ferrando
Journal:  Nat Med       Date:  2010-10-24       Impact factor: 53.440

10.  Upregulation of T-Cell-Specific Transcription Factor Expression in Pediatric T-Cell Acute Lymphoblastic Leukemia (T-ALL).

Authors:  Müge Sayitoğlu; Yücel Erbilgin; Ozden Hatırnaz Ng; Inci Yıldız; Tiraje Celkan; Sema Anak; Omer Devecioğlu; Gönül Aydoğan; Serap Karaman; Nazan Sarper; Cetin Timur; Umit Ure; Uğur Ozbek
Journal:  Turk J Haematol       Date:  2012-12-05       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.